Report
Patient-Led Commercial Targeting in Psoriatic Arthritis (Immunology)
To support the launch of a new Psoriatic Arthritis (PsA) treatment, a global biopharma company leveraged DRG Fusion to overcome the limitations of traditional, prescribing-focused targeting. PsA diagnosis is often delayed due to overlapping symptoms with other conditions and fragmented care across specialties. By using DRG Fusion’s patient-led approach, the company traced real-world patient journeys and uncovered hidden referral pathways—especially from dermatologists and primary care physicians (PCPs) to rheumatologists. This strategy enabled earlier identification of PsA patients, improved coordination across the care network, and optimized field force efforts—leading to faster therapy adoption, better patient outcomes, and greater commercial impact.
Key Takeaways:
Learn how real-world patient journey mapping reveals hidden referral patterns and diagnostic delays in PsA.
Understand the commercial value of targeting upstream HCPs like dermatologists and PCPs—beyond rheumatologists.
See how early engagement with referring providers expands the diagnosed patient pool and accelerates therapy initiation.
Explore the use of patient segmentation to identify subgroups who benefit most from early intervention.
Discover how DRG Fusion improves resource alignment and ROI by prioritizing high-value, early influencers in the care pathway.
